Tradestie Institutional Equity Comparison Engine

RGNX vs RIGL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RIGL Overall Edge

RIGL Captures Institutional Edge (4โ€“0 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Rigel Pharmaceuticals Inc. (New) (RIGL) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, RGNX trades at N/M Forward P/E with -120.4% operating margin (-69.2% YoY revenue) versus RIGL at 9.3x Forward P/E and 26.3% operating margin (+16.5% YoY). In options structure, RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against RIGL sits in CONSOLIDATION (4th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner RIGL
RGNX N/M vs RIGL 9.3x Fwd P/E
Growth & Margin Winner RIGL
Op Margin -120.4% vs 26.3% ยท YoY -69.2% vs +16.5%
Momentum & Technical Winner RIGL
1Y -36.0% vs +9.7% ยท 52W Pos 19% vs 68%
Options & Structure Winner RIGL
BREAKDOWN (52nd %ile IV) vs CONSOLIDATION (4th %ile IV)
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.45
-2.49% 1D
Market Cap $500.9M
1M Return +7.58%
1Y Return -36.0%
Forward P/E N/M
Unified AI Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
RIGL NASDAQ
Rigel Pharmaceuticals Inc. (New)
Pharmaceutical Preparations
$43.74
-1.61% 1D
Market Cap $860.3M
1M Return -4.84%
1Y Return +9.69%
Forward P/E 9.3x
Unified AI Score
59.9 / 100 HOLD
Tech 48.0 Fund 58.0 Flow 68.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RGNX -36.0% RIGL +9.69% Spread: +45.69 pp (RIGL Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period RGNX Revenue RIGL Revenue RGNX Op. Margin RIGL Op. Margin Margin Edge
FY2018 $220M $40M 40.3% -163.3% RGNX
FY2019 $40M $60M -422.9% -116.5% RIGL
FY2020 $150M $110M -77.1% -26.7% RIGL
FY2021 $470M $150M 34.0% -8.4% RGNX
FY2022 $110M $120M -233.2% -46.2% RIGL
FY2023 $90M $120M -297.1% -17.5% RIGL
FY2024 $80M $180M -280.0% 13.5% RIGL
FY2025 $170M $290M -94.6% 42.6% RIGL

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RGNX (0) vs RIGL (10)
Institutional Metric RGNX RIGL Criterion Row Winner
Market Capitalization Scale $500.9M $860.3M Larger Scale RIGL
Trailing P/E Ratio Valuation N/M 2.8x Lower Multiple RIGL
Forward P/E Ratio Valuation N/M 9.3x Lower Multiple RIGL
Revenue Growth (YoY) Growth -69.2% +16.5% Higher Growth RIGL
Operating Margin (TTM) Profitability -120.4% 26.3% Higher Margin RIGL
Net Profit Margin Profitability -113.9% 106.6% Higher Margin RIGL
Return on Equity (ROE) Capital Efficiency -113.2% 109.2% Higher ROE RIGL
52-Week Range Position Momentum 19% ($5โ€“$16) 68% ($25โ€“$53) Stronger Trend RIGL
Beta / 30D Volatility Risk Regime 1.82ฮฒ ยท 76% Vol 1.06ฮฒ ยท 74% Vol Lower Realized Risk RIGL
Unified Institutional Score Composite Signal 45.3 / 100 (HOLD) 59.9 / 100 (HOLD) Higher Composite RIGL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RGNX vs RIGL Buy Guide
RGNX BREAKDOWN
91d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RGNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RIGL CONSOLIDATION
91d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live RIGL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RGNX nor RIGL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.